The Fermiscan Test is a safe, non-invasive technology that utilises X-ray diffraction of hair fibres to screen and monitor women of all ages for breast cancer. The Fermiscan Test will be available for women in Australia in 2008 and Fermiscan is also commencing further clinical trials and regulatory approval processes in the US.
The Fermiscan Test requires individuals to supply 20 strands of untreated scalp hair with a minimum length of 30 mm. The hairs are then exposed to a finely focused X-ray beam for up to 30 s. The diffracted X-rays are collected as an image which is then analysed to determine if subtle changes are present in the image that are indicative of the presence of breast cancer.
Phone: 02 9245 4460
Beckman Coulter Life Sciences Basophil Activation Test (BAT) for food allergy research
Beckman Coulter Life Sciences introduces its next-generation Basophil Activation Test (BAT) to...
TopoGEN Topoisomerase Assay Kits
TopoGEN provides innovative reagents and kits for topoisomerase research and mechanism-based drug...
Alamar Biosciences NULISAseq Mouse Panel 120 for protein biomarker analysis
The multiplex panel encompasses a wide selection of proteins essential for studying key...
